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Abstract
Purpose:  To  examine  the  diagnostic  capability  of  the  full  retinal  and  inner  retinal  thickness
measures in  differentiating  individuals  with  diabetic  peripheral  neuropathy  (DPN)  from  those
without  neuropathy  and  non-diabetic  controls.
Methods:  Individuals  with  (n  =  44)  and  without  (n  =  107)  diabetic  neuropathy  and  non-diabetic
control (n  =  42)  participants  underwent  spectral  domain  optical  coherence  tomography  (SDOCT).
Retinal thickness  in  the  central  1  mm  zone  (including  the  fovea),  parafovea  and  perifovea  was
assessed in  addition  to  ganglion  cell  complex  (GCC)  global  loss  volume  (GCC  GLV)  and  focal
loss volume  (GCC  FLV),  and  retinal  nerve  ﬁber  layer  (RNFL)  thickness.  Diabetic  neuropathy  was
deﬁned using  a  modiﬁed  neuropathy  disability  score  (NDS)  recorded  on  a  0--10  scale,  wherein,
NDS ≥3  indicated  neuropathy  and  NDS  indicated  <3  no  neuropathy.  Diagnostic  performance  was
assessed by  areas  under  the  receiver  operating  characteristic  curves  (AUCs),  95  per  cent  conﬁ-
dence intervals  (CI),  sensitivities  at  ﬁxed  speciﬁcities,  positive  likelihood  ratio  (+LR),  negative
likelihood ratio  (−LR)  and  the  cut-off  points  for  the  best  AUCs  obtained.
Results:  The  AUC  for  GCC  FLV  was  0.732  (95%  CI:  0.624--0.840,  p  <  0.001)  with  a  sensitivity  of  53%
and speciﬁcity  of  80%  for  differentiating  DPN  from  controls.  Evaluation  of  the  LRs  showed  that
GCC FLV  was  associated  with  only  small  effects  on  the  post-test  probability  of  the  disease.  The
cut-off point  calculated  using  the  Youden  index  was  0.48%  (67%  sensitivity  and  73%  speciﬁcity)
for GCC  FLV.  For  distinguishing  those  with  neuropathy  from  those  without  neuropathy,  the  AUCs
of retinal  parameters  ranged  from  0.508  for  the  central  zone  to  0.690  for  the  inferior  RNFL∗ Corresponding author.
E-mail address: sangeetha.srinivasan@connect.qut.edu.au (S. Srinivasan).
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BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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thickness.  For  distinguishing  those  with  moderate  or  advanced  neuropathy  from  those  with  mild
or no  neuropathy,  the  inferior  RNFL  thickness  demonstrated  the  highest  AUC  of  0.820,  (95%  CI:
0.731--0.909,  p  <  0.001)  with  a  sensitivity  of  69%  and  80%  speciﬁcity.  The  cut-off-point  for  the
inferior RNFL  thickness  was  97  m,  with  81%  sensitivity  and  72%  speciﬁcity.
Conclusions:  The  GCC  FLV  can  differentiate  individuals  with  diabetic  neuropathy  from  healthy
controls,  while  the  inferior  RNFL  thickness  is  able  to  differentiate  those  with  greater  degrees
of neuropathy  from  those  with  mild  or  no  neuropathy,  both  with  an  acceptable  level  of  accu-
racy. Optical  coherence  tomography  represents  a  non-invasive  technology  that  aids  in  detection
of retinal  structural  changes  in  patients  with  established  diabetic  neuropathy.  Further  reﬁne-
ment of  the  technique  and  the  analytical  approaches  may  be  required  to  identify  patients  with
minimal  neuropathy.
©  2016  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Capacidad  diagnóstica  de  las  mediciones  del  grosor  de  la  retina  en  la  neuropatía
periférica  diabética
Resumen
Objetivo:  Examinar  la  capacidad  diagnóstica  de  las  mediciones  del  grosor  total  e  interno  de  la
retina, con  diferenciación  entre  individuos  con  neuropatía  periférica  diabética  (DPN),  aquellos
que no  la  padecen,  y  controles  no  diabéticos.
Métodos:  Cuarenta  y  cuatro  individuos  con  (n  =  44)  y  sin  (n  =  107)  neuropatía  diabética  y  par-
ticipantes  de  control  no  diabéticos  (n  =  42)  fueron  sometidos  a  una  tomografía  de  coherencia
óptica de  dominio  espectral  (SDOCT).  Se  evaluó  el  grosor  de  la  retina  en  la  zona  central  de  1  mm
(incluyendo  la  fóvea),  parafóvea  y  perifóvea,  además  del  complejo  de  células  ganglionares
(GCC), el  volumen  de  pérdida  global  (GCC  GLV)  y  el  volumen  de  pérdida  focal  (GCC  FLV),  y  el
espesor de  la  capa  de  ﬁbras  nerviosas  de  la  retina  (RNFL).  Se  deﬁnió  la  neuropatía  diabética
utilizando  la  versión  modiﬁcada  del  ‘‘Neuropathy  Disability  Score  (NDS)’’,  sobre  una  escala
de 0  a  10,  donde  el  valor  de  NDS  ≥3  indicaba  neuropatía  y  NDS  <3  ausencia  de  la  misma.  El
desempen˜o diagnóstico  se  evaluó  mediante  las  áreas  bajo  las  curvas  características  operativas
del receptor  (AUC),  intervalos  de  conﬁanza  del  95%  (IC),  sensibilidades  a  especiﬁcidades  ﬁjas,
cociente  de  probabilidad  positiva  (CP+),  y  cociente  de  probabilidad  negativa  (CP−) y  los  puntos
de corte  para  los  mejores  AUC  obtenidos.
Resultados:  El  AUC  para  GCC  FLV  fue  de  0,732,  95%  IC:  0,624--0,840,  p  <  0,001  con  una  sensi-
bilidad del  53%  y  una  especiﬁcidad  del  80%  para  la  diferenciación  entre  DPN  y  los  controles.  La
evaluación  de  los  CP  reﬂejó  que  el  GCC  FLV  se  asociaba  únicamente  a  unos  pequen˜os  efectos  en
la prueba  posterior  de  probabilidad  de  la  enfermedad.  El  punto  de  corte  calculado  utilizando
el índice  de  Youden  fue  del  0,48%  (67%  de  sensibilidad  y  73%  de  especiﬁcidad)  para  GCC  FLV.
Para distinguir  a  aquellos  individuos  con  neuropatía  de  los  que  no  la  padecían,  las  AUC  de  los
parámetros  retinianos  oscilaron  entre  0,508  para  el  grosor  RNFL  de  la  zona  central  y  0,690  para
el de  la  zona  inferior.  Para  distinguir  a  aquellas  personas  con  neuropatía  moderada  o  avanzada,
de aquellas  con  neuropatía  leve,  o  ausencia  de  ella,  el  grosor  RNFL  de  la  zona  inferior  reﬂejó
una AUC  superior  de  0,820,  95%  IC:  0,731--0,909,  p  <  0,001,  con  una  sensibilidad  del  69%  y  una
especiﬁcidad  del  80%.  El  punto  de  corte  para  el  grosor  RNFL  inferior  fue  de  97  m,  con  un  81%
de sensibilidad  y  un  72%  de  especiﬁcidad.
Conclusiones:  El  GCC  FLV  puede  diferenciar  entre  aquellos  individuos  con  neuropatía  diabética
y los  controles  sanos,  mientras  que  el  grosor  RNFL  de  la  zona  inferior  es  capaz  de  diferenciar
entre aquellas  personas  con  grados  superiores  de  neuropatía  y  aquellas  con  neuropatía  leve  o
ausencia de  neuropatía,  en  ambos  casos  con  un  nivel  aceptable  de  precisión.  La  tomografía  de
coherencia  óptica  supone  una  tecnología  no  invasiva  que  ayuda  a  la  detección  de  los  cambios
estructurales  retinianos  en  pacientes  con  neuropatía  diabética  establecida.  Se  precisa  un  mayor
reﬁnamiento  de  esta  técnica,  así  como  enfoques  analíticos,  para  identiﬁcar  a  aquellos  pacientes
con una  neuropatía  mínima.
©  2016  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Introduction
Peripheral  neuropathy  is  a  devastating  complication  affect-
ing  ∼50%  of  individuals  with  diabetes.1 Neuropathy  affecting
the  sensory  nerves  in  the  feet  and  lower  limbs  can  lead  to
foot  ulceration  and  eventually  amputation.2 Although  symp-
toms  and  signs  and  neurophysiology  are  advocated  in  the
diagnosis  of  diabetic  neuropathy,  they  have  limited  repro-
ducibility  and  wide  variability.  Procedures  such  as  skin  and
nerve  biopsy  are  more  reproducible  and  detect  sub-clinical
neuropathy,  but  are  invasive  and  require  expensive  lab-
oratory  equipment  and  trained  personnel.3 Hence  there
is  a  need  for  a  painless  or  non-invasive,  reproducible,
cost-effective  and  clinically  accessible  means  for  early
detection,  diagnosis,  staging  severity,  and  monitoring  pro-
gression  of  diabetic  peripheral  neuropathy  (DPN).  Several
studies4--10 have  previously  demonstrated  considerable  diag-
nostic  potential  of  OCT  and  corneal  confocal  microscopy
(CCM)  for  imaging  and  monitoring  vascular  and  neural
changes  in  relation  to  diabetes.  Using  spectral  domain  opti-
cal  coherence  tomography  (SDOCT),  we  have  previously
reported  that  the  full  retinal8 and  inner  retinal  thickness8--10
is  signiﬁcantly  reduced  in  individuals  with  neuropathy,  espe-
cially  in  those  who  are  at  increased  risk  of  foot  ulceration.10
This  ﬁnding  was  independent  of  diabetic  retinopathy  (DR).
OCT  aids  in  the  non-contact  evaluation  of  retinal  layers
in  vivo  at  a  near-microscopic  resolution  to  provide  informa-
tion  regarding  the  speciﬁc  layer  of  interest.  Over  the  years,
OCT  has  become  an  indispensable  technology  for  clinicians
in  the  assessment  of  ocular  diseases  and  ocular  manifesta-
tions  of  systemic  diseases  and  has  revolutionized  the  way
in  which  ophthalmologists,  optometrists  and  other  eye  care
practitioners  can  assess  various  retinal  and  vitreoretinal  dis-
eases.
Given  that  OCT  can  detect  diabetes-related  compromise
in  multiple  layers  of  the  retina,  we  sought  to  assess  the
diagnostic  potential  of  the  OCT-derived  retinal  parameters
in  differentiating  individuals  with  diabetes  with  neuropathy
from  those  without  neuropathy  and  non-diabetic  individuals.
We  assessed  the  diagnostic  capability  of  the  SDOCT-
derived  retinal  parameters  in  identifying  individuals  with
diabetic  peripheral  neuropathy  (DPN).
Methods
The  study  received  ethics  clearance  from  the  institutional
Human  Research  Ethics  Committees  of  the  host  University
and  the  collaborative  hospitals,  and  was  conducted  accord-
ing  to  the  Tenets  of  Declaration  of  Helsinki  as  revised  in
2008.  One-hundred  and  ﬁfty  one  people  with  diabetes  (84
with  type  1  and  67  with  type  2  diabetes)  and  42  people
without  diabetes  or  neuropathy  were  enrolled  as  healthy
controls.  Participants  provided  written  informed  consent
prior  to  involvement.
Inclusion  and  exclusion  criteria
Participants  underwent  visual  acuity  assessment  (Bailey-
Lovie  logMAR  chart,  Multimedia  Centre,  School  of  Optom-
etry,  University  of  California,  Berkeley,  CA,  USA)  assessed  at
20  ft,  slit  lamp  biomicroscopy  (Haag-Streit,  Bern,  Switzer-
land),  intra  ocular  pressure  measurement  (ICare®,  Tiolat,
N
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y,  Helsinki,  Finland)  and  three-ﬁeld  fundus  photography
Visucam  Pro,  Carl  Zeiss  Meditec  Inc.,  Dublin,  CA,  USA).
hree  consecutive  readings  of  intra  ocular  pressure  mea-
urements  were  obtained  and  averaged.  Dilated  fundus
hotography  was  performed  using  Tropicamide  ophthalmic
olution  1%  (Alcon  Laboratories,  Inc.,  Fort  Worth,  Texas  for
andoz  Inc.  Princeton,  NJ,  USA).  Individuals  who  were  40
ears  or  older  with  best-corrected  visual  acuity  of  20/30  or
etter,  refractive  error  within  ±6.00D sphere  or  astigma-
ism  within  ±3.00D cylinder  were  included.  Individuals  with
ataract  that  prevented  a  satisfactory  view  of  the  poste-
ior  segment  with  retinal  imaging  techniques,  any  history  of
etinal  photocoagulation,  diagnosis  or  reasonable  suspicion
f  glaucoma  from  optic  nerve  head  appearance,  any  history
f  intra-ocular  pressure  above  22  mmHg,  and  any  neurolog-
cal  condition  that  might  affect  retinal  nerve  ﬁbers  (e.g.
arkinson’s  disease11 or  multiple  sclerosis12)  were  excluded.
undus  photographs  were  examined  by  an  ophthalmologist
ho  was  masked  to  the  details  of  the  participant  to  rule  out
etinal  pathologies  other  than  those  due  to  diabetes,  and
he  presence  or  absence  of  DR  was  noted.
For  the  control  group,  in  addition  to  the  above  criteria,
articipants  were  excluded  if  they  had  diabetes,  a  positive
nti-glutamic  acid  decarboxylase  (anti-GAD)  antibody  or  a
europathy  due  to  any  other  cause.  Glutamic  acid  decar-
oxylase  (GAD)  is  a  protein  identiﬁed  in  the  beta  cells  of
he  pancreas.  A  positive  result  for  anti-GAD  or  GAD  antibod-
es  suggests  marker  that  is  more  commonly  associated  with
ype  1  diabetes.
Peripheral  neuropathy  may  also  be  associated  with  other
tiologies  such  as  autoimmune  diseases  like  rheumatoid
rthritis,13 infectious  diseases  such  as  Hansen’s  disease,14
cquired  immune  deﬁciency  syndrome,15 certain  toxic  sub-
tances  like  alcohol,16 vitamin  deﬁciency,17 and  chronic
xposure  to  radiation,  trauma,  and  tumors  exerting  pressure
n  the  spinal  cord.18 Therefore,  individuals  with  a  history  of
europathy  due  to  non-diabetic  causes  were  excluded  from
he  study.
All  participants  underwent  HbA1c testing  on  the  day  of
he  ophthalmic  exam.  The  HbA1c is  also  known  as  glyco-
ylated  or  glycated  hemoglobin.  HbA1c is  a  component  of
emoglobin  A1c (HbA1c)  to  which  the  glucose  is  bound.  HbA1c
evels  are  reﬂective  of  glycemic  control  over  the  previous
ix  to  eight  weeks  and  are  not  affected  by  daily  ﬂuctuations
n  blood  glucose  levels.  The  American  Diabetes  Association
ow  recommends  using  HbA1c for  the  diagnosis  of  diabetes.
In  addition,  individuals  identifying  as  ‘without  diabetes’
nderwent  fasting  plasma  glucose  testing  and  were  included
nly  if  the  fasting  glucose  level  was  in  the  normal  range.  Any-
ne  with  abnormal  fasting  plasma  glucose  underwent  an  oral
lucose  tolerance  test;  all  individuals  in  the  control  group
ad  fasting  glucose  in  the  normal  range.  The  eye  on  the
ide  of  the  dominant  hand  was  tested  unless  contraindicated
y  the  above  exclusion  criteria,  in  which  case,  the  eye  on
he  non-dominant  side  was  tested.  Dominant  hand  was  by
elf-report.europathy  assessment
ndividuals  underwent  neuropathy  evaluation  and  were  clas-
iﬁed  as  with  or  without  neuropathy  according  to  a  modiﬁed
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europathy  disability  score  (NDS)  which  involved  neuro-
ogical  examination  of  vibration  perception,  sharp/blunt
ensation,  temperature  sensation  using  a  Neurotip® device
Owen  Mumford  Ltd.,  Oxford,  UK),  and  ankle  reﬂexes.  A
core  of  0 is  given  for  a  normal  response  and  1  for  an  abnor-
al  response  for  each  individual  test  component.  The  ankle
eﬂex  was  assessed  using  a  reﬂex  hammer  with  the  scores
eing  0  for  normal,  1  for  reinforcement  and  2  for  absent.
ach  foot  can  have  a  maximum  score  of  5  resulting  in  a
otal  score  of  10  for  both  feet.  An  NDS  ≥3  is  indicative
f  neuropathy,  with  higher  scores  indicating  more  severe
isease.19
ptical  coherence  tomography
ptical  coherence  tomography  (RTVue  SDOCT,  Model  RT-
00,  ver.4.0,  Fremont,  CA,  USA)  was  used  to  examine  full
etinal  and  inner  retinal  thickness.  OCT  described  in  this
ork  employs  a  wavelength  of  820  ±  10  nm  from  a  super-
uminescent  diode.  The  beam  is  split  into  a  reference
rm  that  is  sent  to  a  mirror  and  the  other  that  is  sent
o  the  ocular  tissue.  The  reﬂected  beam  from  the  ocu-
ar  tissue  and  that  from  the  mirror  create  an  interference
attern,  which  is  split  by  a  grating  into  different  wave-
ength  components.  Fourier  transformation  is  then  applied
o  give  A-scans.  The  software  acquires  26,000  A-scans  per
econd  with  an  axial  resolution  of  5  m  (adapted  from
TVue  User  Manual  ver.4.0).  Full  retinal  thickness  is  mea-
ured  along  12  radial  lines,  each  6  mm  long,  centered  at
he  fovea  and  averaged  at  three  regions.  The  outermost
egion  is  the  perifoveal  zone  deﬁned  by  the  area  between
n  inner  circle  with  a  diameter  of  3  mm  and  an  outer
ircle  with  a  diameter  of  6  mm.  The  middle  parafoveal
one  is  similarly  deﬁned  by  an  inner  circle  (1  mm  diame-
er)  and  an  outer  circle  (3  mm  diameter).  The  innermost
t
t
n
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Figure  1  Schematic  of  the  retinal  zoneS.  Srinivasan  et  al.
one  is  contained  within  the  circle  of  diameter  1  mm  and
ncludes  the  fovea.  Fig.  1  is  a  schematic  of  the  retinal  zone
ssessed  for  full  retinal  thickness.  Retinal  nerve  ﬁber  layer
hickness  (RNFL)  is  measured  between  the  inner  plexiform
ayer  and  inner  limiting  membrane  boundaries,  along  a  cir-
le  of  3.45  mm  diameter  centered  at  the  optic  nerve  head.
anglion  cell  complex  (GCC)  is  a  composite  of  the  inner
lexiform  layer,  ganglion  cell  layer  and  nerve  ﬁber  layer;  it
s  interpolated  from  measurements  along  15  vertical  lines
nd  one  horizontal  line,  covering  a  zone  of  7  mm  ×  7  mm
hat  is  centered  1  mm  temporal  to  the  fovea.  Fig.  2  is  a
chematic  of  the  retinal  zones  assessed  for  the  inner  retinal
hickness.
Two  pattern-based  GCC  parameters  namely,  focal  loss
olume  (GCC  FLV)  and  global  volume  (GCC  GLV)  were
ssessed.  The  GCC  GLV  reﬂects  the  average  amount  of  GCC
oss  over  the  entire  GCC  map  and  is  analogous  in  concept
o  the  mean  deviation  (MD)  of  the  visual  ﬁelds.  The  GCC
LV  detects  focal  loss  after  correcting  for  the  overall  sink-
ng  or  the  general  depression  of  the  topography  of  the  GCC
hickness  map  and  is  analogous  to  pattern  standard  deviation
PSD)  measurement  in  visual  ﬁelds.20
The  overall,  superior  hemisphere  and  inferior  hemisphere
hicknesses  of  the  parafovea,  perifovea,  RNFL  and  GCC,  as
ell  as  central  undivided  zone  thickness,  GCC  FLV  and  GCC
LV  were  each  considered  for  analysis.
tatistical  analysis
ata  were  analyzed  using  the  Statistical  Packages  for  the
ocial  Sciences  (SPSS  version  17.0).  Participant  characteris-
ics  were  assessed  in  the  three  groups  after  examining  for
he  normality  of  distribution.  Full  retinal  and  inner  reti-
al  thickness  were  normally  distributed  and  hence  were
ompared  between  groups  using  ANOVA;  a  Tukey’s  test
 assessed  for  full  retinal  thickness.
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those  without  DPN  (p  <  0.001).  The  proportion  of  males  was
similar  in  the  groups  with  and  without  DPN  (2(1,151) =  2.505,Figure  2  Schematic  of  the  retinal  z
was  performed  as  a  post  hoc  test  for  those  variables  that
were  signiﬁcant  with  the  ANOVA  test.  The  FLV  and  GLV
were  not  normally  distributed;  therefore,  group  differ-
ences  were  assessed  using  Kruskal--Wallis  test  followed  by
a  Mann--Whitney  U  test  for  a  post  hoc  analysis.  The  diagnos-
tic  performance  was  assessed  by  areas  under  the  receiver
operating  characteristic  curves  (AUCs)  and  95  per  cent  conﬁ-
dence  interval  (CI),  sensitivities  at  80%  and  95%  speciﬁcity
levels.  Positive  and  negative  likelihood  ratios  (LR)  and  the
diagnostic  threshold  (determined  by  the  Youden  index)  were
calculated  for  the  best  AUCs  observed.
p
b
Table  1  Clinical  characteristics  of  participants  in  the  groups  with
Variables Neuropathy
(A)
Mean  ±  SD
Min--Max
n  =  44
No  neuro
(B)
Mean  ±  SD
Min--Max
n  =  107
Age  (years)
59  ±  8  55  ±  9  
41--71 40--77  
Males, n  (%) 30  (68%)  58  (54%)  
HbA1c (%)
8.0  ±  1.3 7.7  ±  1.3
6--13 5--12  
Duration  of
diabetes  (years)
22  ±  15  16  ±  12  
6--64 1--53
DR, n  (%)  27  (61%)  36  (34%)  
NDS (0--10)
5.1  ±  2.1  0.6  ±  0.7
3--10 0--2  
DR, diabetic retinopathy; NDS, neuropathy disability score.assessed  for  inner  retinal  thickness.
esults
articipant  characteristics
able  1  provides  a  summary  of  the  participant  characteris-
ics.  Individuals  with  DPN  were  signiﬁcantly  older  than  those
ithout  DPN  and  had  a  longer  duration  of  diabetes  than =  0.114).  The  HbA1c levels  did  not  differ  signiﬁcantly
etween  diabetic  patients  with  and  without  DPN,  but  both
 and  without  diabetic  neuropathy  and  control  subjects.
pathy Controls
(C)
Mean  ±  SD
Min--Max
n  =  42
ANOVA  P  (sig.  diff.
in  post  hoc)
55  ±  9  0.021  (A  vs.  B)
40--73
20  (44%)  0.114
 5.4  ±  0.3  <0.001  (A,  B  vs.  C)
5--6
n/a  <0.001
n/a  0.002
 0.3  ±  0.6  <0.001  (A  vs.  B,  C)
0--2
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roups  had  signiﬁcantly  higher  HbA1c levels  compared  to
ontrols  (p  <  0.001).  The  NDS  was  4.5  units  greater  in  the
PN  group  on  average  compared  to  the  group  without  DPN
p  < 0.001).  The  proportion  of  people  with  DR  was  signif-
cantly  higher  among  those  with  DPN  (61%)  compared  to
hose  without  DPN  (34%).  A  Chi-square  test  of  independence
emonstrated  a  signiﬁcant  relationship  between  DPN  and
he  presence  of  retinopathy  (2(1,151) =  9.852,  p  =  0.002).
iagnostic  capability
iabetic  peripheral  neuropathy  (DPN+)  versus
on-diabetic  (control)  group
able  2  provides  a  summary  of  the  diagnostic  performance
or  retinal  variables  comparing  individuals  with  DPN  to
on-diabetic  controls.  The  AUC  for  GCC  FLV  (0.732,  95%
I:  0.624--0.840,  p  <  0.001,  with  54%  sensitivity  at  80%
a
t
r
p
Table  2  Diagnostic  accuracy  of  SDOCT  parameters  in  differentiat
controls.
Variable  DPN  Non-
diabetic
controls
AUC  ±  SE  
Central  1  mm
zone
246  ±  19
207--286
254  ±  26
180--313
0.622  ±  0.062  
Overall
parafovea
304 ±  14
271--330
314  ±  14
277--341
0.696  ±  0.057  
Superior
parafovea
307 ±  14
274--332
318  ±  14
285--341
0.708  ±  0.056  
Inferior
parafovea
302 ±  14
262--328
311  ±  14
269--342
0.674  ±  0.058  
Overall
perifovea
264 ±  13
233--289
272  ±  13
236--301
0.656  ±  0.059  
Superior
perifovea
270 ±  15
234--297
278  ±  13
242--306
0.660  ±  0.059  
Inferior
perifovea
258 ±  15
207--285
265  ±  16
222--312
0.619  ±  0.061  
Overall RNFL  97  ±  9
71--120
102  ±  11
74--132
0.669  ±  0.058  
Superior RNFL  98  ±  10
75--119
102  ±  13
66--135
0.636  ±  0.060  
Inferior RNFL  97  ±  9
75--119
102  ±  12
82--136
0.669  ±  0.058  
Overall GCC  93  ±  7
77--112
96  ±  7
76--108
0.638  ±  0.061  
Superior GCC  93  ±  7
75--112
95  ±  8
70--110
0.619  ±  0.062  
Inferior GCC  93  ±  8
71--112
97  ±  6
81--108
0.653  ±  0.060  
GCC FLV  0.97a
0.00--6.18
0.24
0.00--3.87
0.732  ±  0.055  
GCC GLV  5.38a
0.02--21.48
2.44
0.02--14.19
0.648  ±  0.060  
Data represent mean ± SD, range; Data are represented in m except
CI, conﬁdence interval; SE, standard error; AUC, areas under the rec
neuropathy; RNFL, retinal nerve ﬁber layer; GCC, ganglion cell comp
p-values in bold.
a Median values.S.  Srinivasan  et  al.
peciﬁcity)  demonstrated  fair  diagnostic  capacity  (Fig.  3).
he  AUCs  for  other  retinal  variables  namely  central  zone
p  =  0.055),  inferior  perifovea  (p  =  0.060)  and  inferior  GCC
p  =  0.061)  did  not  differ  from  the  line  of  no  discrimination.
iabetes  with  neuropathy  (DPN+)  versus  diabetes
ithout  neuropathy  (DPN−)
able  3  provides  a  summary  of  the  diagnostic  performance
or  retinal  variables  comparing  individuals  with  and  without
PN.  The  AUCs  ranged  from  0.508  for  the  central  retinal
one  to  0.690,  for  the  inferior  hemisphere  RNFL  thickness.
he  retinal  parameters  demonstrated  poor  accuracy  for  dif-
erentiating  diabetic  patients  with  and  without  DPN.  The
UCs  for  central  retinal  zone  (p  =  0.876),  GCC  FLV  (p  =  0.736)
nd  GCC  GLV  (p  =  0.706)  did  not  differ  signiﬁcantly  from
hat  due  to  chance.  For  DPN+  versus  controls,  the  GCC  FLV
evealed  fair  diagnostic  accuracy  relative  to  the  other  com-
arisons.
ing  diabetic  patients  with  neuropathy  (DPN)  and  non-diabetic
95%  CI  p-Value
for  AUC
Sensitivity
at  80%
speciﬁcity
Sensitivity
at  95%
speciﬁcity
0.500--0.743  0.055  41.9%  0.0%
0.584--0.808  0.002  51.2%  11.6%
0.598--0.819  0.001  51.2%  2.0%
0.559--0.788  0.006  46.5%  14%
0.540--0.773  0.014  44.2%  9.3%
0.544--0.777  0.011  44.2%  30.2%
0.499--0.740  0.060  39.5%  9.3%
0.555--0.783  0.007  43.2%  9.1%
0.518--0.753  0.030  27.3%  11.4%
0.556--0.783  0.007  21.4%  13.6%
0.519--0.757  0.029  34.9%  14.0%
0.497--0.741  0.061  32.6%  7.0%
0.536--0.770  0.016  37.2%  27.9%
0.624--0.840  <0.001  53.5%  20.9%
0.529--0.767  0.020  30.2%  14%
 GCC FLV and GCC GLV which are represented in percentage (%);
eiver operating characteristic curves; DPN, diabetic peripheral
lex; FLV, focal loss volume; GLV, global loss volume; signiﬁcant
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Table  3  Diagnostic  accuracy  of  SDOCT  parameters  in  differentiating  diabetic  patients  with  neuropathy  (DPN)  and  diabetic
patients without  neuropathy  (No  DPN).
Variable  DPN  No  DPN  AUC  ±  SE  95%  CI  p-Value
for  AUC
Sensitivity
at  80%
speciﬁcity
Sensitivity
at  95%
speciﬁcity
Central  1  mm
zone
246  ±  19
207--286
245  ±  26
140--293
0.508  ±  0.050  0.410--0.606  0.876  11.6%  2.3%
Overall
parafovea
304 ±  14
271--330
310  ±  17
259--342
0.620  ±  0.048  0.525--0.715  0.022  30.2%  2.3%
Superior
parafovea
307 ±  14
274--332
313  ±  17
254--349
0.616  ±  0.049 0.520--0.712 0.027 32.6%  1.7%
Inferior
parafovea
302 ±  14
262--328
307  ±  17
246--343
0.621  ±  0.048  0.526--0.715  0.021  30.2%  2.3%
Overall
perifovea
264 ±  13
233--289
271  ±  15
201--301
0.653  ±  0.049  0.557--0.749  0.003  44.2%  4.7%
Superior
perifovea
270 ±  15
234--297
277  ±  15
228--313
0.622  ±  0.052 0.521--0.723 0.019  44.2%  4.7%
Inferior
perifovea
258 ±  15
207--285
265  ±  16
170--302
0.637  ±  0.051  0.538--0.736  0.009  39.5%  14%
Overall RNFL  97  ±  9
71--120
104  ±  11
75--136
0.682  ±  0.045  0.593--0.770  <0.001  43.0%  6.8%
Superior RNFL  98  ±  10
75--119
104  ±  12
76--136
0.638  ±  0.047  0.546--0.729  <0.001  29.5%  9.1%
Inferior RNFL  97  ±  9
75--119
105  ±  12
74--137
0.690  ±  0.046  0.601--0.779  <0.001  40.9%  6.8%
Overall GCC  93  ±  7
77--112
96  ±  8
71--117
0.614  ±  0.049  0.517--0.710  0.030  34.9%  4.7%
Superior GCC  93  ±  7
75--112
96  ±  8
70--118
0.611  ±  0.049  0.515--0.707  0.034  32.6%  4.7%
Inferior GCC  93  ±  8
71--112
97  ±  8
73--118
0.608  ±  0.050  0.510--0.706  0.039  32.6%  4.7%
GCC FLV  0.97a
0.00--6.18
0.41
0.00--5.78
0.635  ±  0.051  0.010--0.535  0.736  37.2%  25.6%
GCC GLV  5.38a
0.02--21.48
3.36
0.00--24.20
0.609  ±  0.050  0.037--0.512  0.706  32.6%  4.7%
Data represent mean ± SD and range; Data are represented in m except GCC FLV and GCC GLV which are represented in percentage
(%); CI, conﬁdence interval; SE, standard error; AUC, areas under the receiver operating characteristic curves; DPN, diabetic peripheral
neuropathy; RNFL, retinal nerve ﬁber layer; GCC, ganglion cell complex; FLV, focal loss volume; GLV, global loss volume; signiﬁcant
p-values in bold.
a Median values.
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Figure  3  ROC  curve  for  GCC  FLV,  AUC  =  0.732,  95%  CI:
0.624--0.840,  p  <  0.001.
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iiabetes,  with  mild  or  no  neuropathy  versus  moderate
r  advanced  neuropathy:
able  4  provides  a  summary  of  the  diagnostic  performance
or  retinal  variables  comparing  individuals  with  mild/no  DPN
nd  versus  moderate/advanced  DPN.  The  AUC  was  the  max-
mum  for  inferior  hemisphere  RNFL  thickness,  0.820  (95%
I:  0.731--0.909,  p  <  0.001)  with  a sensitivity  of  69%  and
0%  speciﬁcity  (Fig.  4).  The  thickness  in  the  central  zone
p  =  0.547)  and  inferior  perifovea  (p  =  0.057)  did  not  differ
igniﬁcantly  from  the  line  of  no  discrimination.
The  positive  (+LR)  and  negative  (−LR)  likelihood  ratios
ere  examined  only  for  GCC  FLV  and  for  inferior  RNFL  thick-
ess  for  their  respective  group  comparisons  (Table  5).  Both
ere  associated  with  only  small  effects  on  the  post-test
robability  of  disease.
In  addition,  the  cut-off  point  calculated  using  the  Youden
ndex  for  GCC  FLV  was  0.48%  with  67%  sensitivity  and  73%
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Table  4  Diagnostic  accuracy  of  SDOCT  parameters  in  differentiating  diabetic  patients  with  no  or  mild  neuropathy  versus  moderate  or  advanced  DPN.
Variable  NDS  (6--10)
(n  =  16)
NDS  (0--5)
(n  =  134)
AUC  ±  SE  95%  CI  p-Value
for  AUC
Sensitivity
at  80%
speciﬁcity
Sensitivity
at  95%
speciﬁcity
Central  1  mm  zone  243  ±  23
207--284
246  ±  25
141--293
0.546  ±  0.074  0.400--0.692  0.547  25.0%  12.5%
Overall parafovea  300  ±  14
271--325
310  ±  16
260--342
0.695  ±  0.064  0.57--0.821  0.011  31.3%  6.3%
Superior parafovea 302  ±  14
280--328
313  ±  17
255--350
0.706  ±  0.066  0.577--0.835  0.007  43.8%  0.0%
Inferior parafovea  298  ±  15
263--322
307  ±  17
247--344
0.678  ±  0.064  0.551--0.804  0.020  37.5%  12.5%
Overall perifovea  260  ±  13
234--280
271  ±  15
201--302
0.720  ±  0.058  0.606--0.834  0.004  43.8%  12.5%
Superior perifovea  266  ±  11
253--288
277  ±  16
229--313
0.729  ±  0.059  0.613--0.844  0.003  56.3%  0.0%
Inferior perifovea  255  ±  20
208--286
265  ±  16
171--303
0.646  ±  0.080  0.489--0.803  0.057  50.0%  12.5%
Overall RNFL  92  ±  8
72--106
104  ±  11
75--137
0.788  ±  0.047  0.695--0.881  <0.001  68.8%  12.5%
Superior RNFL  95  ±  10
75--111
104  ±  12
77--137
0.711  ±  0.060  0.593--0.829  0.006  43.8%  12.5%
Inferior RNFL  90  ±  10
68--106
104  ±  12
74--137
0.820  ±  0.045  0.731--0.909  <0.001  68.8%  12.5%
Overall GCC  91  ±  6
77--101
97  ±  8
72--117
0.711  ±  0.062  0.589--0.832  0.006  56.3%  6.3%
Superior GCC  91  ±  6
75--101
97  ±  8
70--119
0.702  ±  0.060  0.584--0.820  0.008  43.8%  6.3%
Inferior GCC  90  ±  7
79--105
97  ±  9
71--119
0.729  ±  0.064  0.603--0.854  0.003  56.3%  12.5%
GCC FLV  2.23a
0.04--5.57
1.04
0.00--6.18
0.703  ±  0.070  0.566--0.841  0.008  43.8%  31.3%
GCC GLV  8.36a
0.65--21.48
4.74
0.00--24.2
0.746  ±  0.060  0.627--0.864  0.001  56.3%  6.3%
Data represent mean ± SD and range; Data are represented in m except GCC FLV and GCC GLV which are represented in percentage (%); CI, conﬁdence interval; SE, standard error; AUC,
areas under the receiver operating characteristic curves; NDS, neuropathy disability score; RNFL, retinal nerve ﬁber layer; GCC, ganglion cell complex; FLV, focal loss volume; GLV, global
loss volume; signiﬁcant p-values in bold.
a Median values.
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Table  5  Diagnostic  capacity  GCC  FLV  and  inferior  hemisphere  RNFL  thickness.
AUC  p-Value  for  AUC  80%  speciﬁcity  95%  speciﬁcity
DPN  (±)  versus  Controls:
GCC FLV
0.732 <0.001
+LR  2.67  +LR  4.00
−LR 0.50  −LR  0.84
Mild/no DPN  versus  mod/adv.  DPN:
Inferior  RNFL
0.802 0.001
+LR  3.42  +LR  2.40
−LR 0.39  −LR  0.92
GCC FLV is represented in %; RNFL is represented in m; AUC, areas under the receiver operating characteristic curves; Mod/adv,
moderate or advanced; DPN, diabetic peripheral neuropathy; +LR, po
focal loss in ganglion cell complex volume.
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in  the  absence  of  clinical  signs  of  DR.  Therefore,  eyeFigure  4  ROC  curve  for  RNFL  thickness  in  inferior  hemisphere,
AUC =  0.820,  95%  CI:  0.731--0.909,  p  <  0.001.
speciﬁcity  and  for  inferior  hemisphere  RNFL  thickness  was
97  m,  with  81%  sensitivity  and  72%  speciﬁcity.
Discussion
This  study  sought  to  examine  if  retinal  thickness  measures
assessed  by  SDOCT  can  differentiate  individuals  with  DPN
from  those  without  DPN  and  non-diabetic  participants.  The
main  ﬁndings  of  the  study  was  that  (i)  OCT  demonstrates
fair  diagnostic  capacity  in  diagnosing  or  differentiating  those
with  DPN  from  non-diabetic  participants  and  also  in  differ-
entiating  moderate  or  advanced  stage  of  DPN  from  mild  or
no  DPN.  (ii)  OCT-derived  parameters  have  limited  diagnostic
capacity  in  detecting  individuals  with  DPN  (or  ruling-in  the
disease)  but  show  some  promise  in  ruling-out  the  disease
(high  speciﬁcity).
Peripheral  neuropathy  is  a  major  complication  of  dia-
betes  and  currently  there  is  a  limited  availability  of
diagnostic  facilities  for  early  detection.1,2 Novel  ophthalmic
techniques  such  as  corneal  confocal  microscopy  and  non-
contact  corneal  aesthesiometry  show  promise  in  this  regard.
These  techniques  have  been  utilized  in  the  identiﬁcation
of  patients  with  minimal  and  more  advanced  diabetic  DPN,
and  can  grade  the  severity  of  DPN.4--6 More  recently  they
have  been  proven  to  be  comparable  to  intraepidermal
nerve  ﬁber  density  --  the  current  gold  standard  for  diag-
nosing  patients  with  early  DPN.6 Recently,  Pritchard  et  al.7
demonstrated  that  corneal  confocal  microscopy  (CCM)  can
predict  4-year  incident  neuropathy  with  an  AUC  of  0.66  at  a
c
r
csitive likelihood ratio; −LR, negative likelihood ratio; GCC FLV,
ut-off  value  of  14.1  mm/mm2 for  corneal  nerve  ﬁber
ength.  In  the  present  study,  the  assessment  of  retinal
arameters  using  OCT  shows  limited  utility  as  a  non-invasive
phthalmic  marker  for  ruling-in  DPN  but  has  better  diag-
ostic  capability  to  rule-out  DPN.  Further  study  with  more
etailed  quantiﬁcation  taking  into  account  retinal  and  sys-
emic  confounding  factors  is  required  to  fully  understand  the
tility  of  quantifying  retinal  neuronal  pathology  using  OCT
n  diabetic  neuropathy.
The  objective  of  this  work  was  to  examine  whether
DOCT-derived  parameters  such  as  full  retinal  and  inner  reti-
al  thicknesses  can  differentiate  diabetic  patients  with  DPN
rom  non-diabetic  individuals  and  diabetic  patients  without
PN.  We  examined  the  sensitivity  at  ﬁxed  speciﬁcity  lev-
ls,  namely  at  80%  and  95%.  One  may  choose  to  have  a  test
ith  high  sensitivity  for  detecting  a disease  (ruling-in  the
isease).  This  method  would  ensure  that  most  if  not  all  of
hose  with  DPN  will  be  detected,  but  this  would  also  result
n  higher  false  positives.  Choosing  a  highly  sensitive  test  will
lso  falsely  label  a  normal  person  as  having  a  disease.  As  a
esult,  we  would  be  subjecting  the  false  positives  to  more
laborate  and  time-consuming  traditional  neuropathy  tests.
echniques  such  as  quantitative  sensory  testing  (QST)3 and
lectrophysiology4 can  quantify  nerve  function  but  have  con-
iderable  limitations  in  terms  of  reproducibility.  Whilst  skin
nd  nerve  biopsies  serve  to  more  accurately  quantify  early
europathy,  they  are  invasive  procedures,  and  also  require
onsiderable  laboratory  expertise.  The  cut-off  points  for
CC  FLV  was  0.48%  with  67%  sensitivity  and  73%  speciﬁcity
hile  that  for  inferior  RNFL  thickness  was  97  m,  with  81%
ensitivity  and  72%  speciﬁcity.  This  shows  early  promise.
Optical  coherence  tomography  is  simple,  non-invasive,
uick  to  perform  and  cost-effective  and  has  evolved  as  a
tandard  clinical  technique  in  the  evaluation  and  further
anagement  of  retinal  and  optic  nerve  disease.  As  a  highly
ascularized  and  innervated  tissue,  the  retina  is  implicated
n  neurological  complications  of  diabetes  and  is  therefore
 candidate  to  serve  as  an  ophthalmic  marker  of  DPN.21
he  nature  and  extent  of  compromise  of  retinal  structural
ntegrity  has  been  characterized  in  individuals  suffering
rom  diabetic  peripheral  neuropathy  using  OCT.
Our  previous  study  demonstrated  that  diabetic  neurop-
thy  is  a  risk  factor  for  compromised  retinal  structural
ntegrity  in  patients  with  diabetes,  independent  of  dia-
etic  retinopathy.8--10 As  such,  neuropathy  may  be  presentare  practitioners  must  note  that  the  absence  of  diabetic
etinopathy  does  not  rule  out  any  retinal  or  neuoretinal
omplications  of  diabetes.  Individuals  can  have  undiagnosed
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neuropathy  is  limited.  This  may  reﬂect  on  the  need  for  more24  
iabetic  peripheral  neuropathy  and  its  associated  neuroreti-
al  complications.  Due  to  the  transparent  nature  of  the
etinal  nerve  ﬁber  layer,  a  compromise  to  the  neural  layers
n  relation  to  diabetic  neuropathy  may  or  may  not  be  notice-
ble  during  a  routine  eye  examination.  DPN  is  a  debilitating
ondition  for  which  there  is  no  effective  treatment  as  yet.
herefore,  screening,  early  detection  and  timely  referral
re  indicated.  The  OCT-derived  parameters  may  be  utilized
or  identiﬁcation  of  individuals  who  need  to  be  referred
o  their  health  care  provider  for  appropriate  investigations
or  undiagnosed  neuropathic  complications  of  diabetes.  This
ould  help  in  intervening  at  the  early  stages  so  that  any
voidable  complications  can  be  prevented.  Conversely,  once
hese  retinal  ﬁndings  have  been  established  as  markers,
phthalmic  screening  may  detect  a  previously  undiagnosed
europathy.
If the  various  ophthalmic  markers  of  diabetic  neuropathy
uch  as  the  potential  retinal  markers  investigated  in  this
tudy  are  eventually  validated,  then  eye  care  practitioners
ay  become  an  important  part  of  multidisciplinary  teams,21
ncluding  diabetic  physicians  and  podiatrists.  Ophthalmolo-
ists,  optometrists  and  opticians  may  possibly  have  a  role
n  the  co-management  of  patients  with  DPN.  A  timely  refer-
al  and  management  plan  can  prevent  or  delay  unnecessary
onsequences.
With  further  validation,  these  ophthalmic  markers  could
ecome  established  as  rapid,  painless,  non-invasive,  sen-
itive,  reiterative,  cost-effective,  and  clinically  accessible
eans  of  screening  for  early  detection,  diagnosis,  stag-
ng  severity,  and  monitoring  progression  of  DPN,  as  well
s  assessing  the  effectiveness  of  possible  therapeutic
nterventions.  In  the  future,  research  may  pave  the
ay  for  an  expanded  role  for  the  ophthalmic  profes-
ions  in  diabetes  management  in  screening  for  diabetic
omplications  such  as  retinopathy  and  neuropathy.  These
ndings  not  only  extend  our  understanding  of  the  patho-
ogical  processes  involved  in  diabetic  neuropathy  but
lso  offer  novel  ophthalmic  approaches  to  the  diagno-
is  and  possible  monitoring  paradigms  of  this  debilitating
ondition.
There  is  currently  no  single,  effective,  valid  means  to
iagnose  diabetic  peripheral  neuropathy.  It  is  possible  that
phthalmic  markers  may  offer  a  viable  alternative  or  a  sub-
titute  to  the  current  screening  methods  for  DPN  and  may
ecrease  the  need  for  painful,  expensive  and  invasive  pro-
edures  such  as  skin  or  nerve  biopsies.21
We  used  spectral  domain  OCT  (SDOCT)  because  of
ts  known  improved  resolution  than  the  contemporary
ime  domain  OCTs  (TDOCT)  available  then,  and  for  better
etailed-oriented  imaging.  Spectral  domain  OCT  measures
igher  retinal  thickness  than  TDOCT  and  is  likely  due  to  the
ifferences  in  the  deﬁnition  of  the  retinal  boundaries  used
y  the  segmentation  algorithms.  We  included  a  non-diabetic
ontrol  group  with  which  we  have  made  comparisons  and
oth  the  cases  and  control  groups  were  examined  using  the
ame  technology.  We  demonstrate  that  the  SDOCT  tech-
ology  described  in  this  work  is  capable  of  differentiating
hose  with  neuropathy  from  the  non-diabetic  control  group
nd  may  prove  to  be  a  useful  technology  for  identifying
iabetic  neuropathy  in  an  ophthalmological/optometric
et  up.  Nevertheless,  the  technologies  cannot  be  used
nterchangeably,  especially  between  patient-visits.
r
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We  show  that  retinal  parameters  have  fair  to  poor  diag-
ostic  accuracy  in  identifying  those  with  DPN  compared  to
atients  without  DPN  and  non-diabetic  individuals.  A  likely
xplanation  could  be  that  a  NDS  of  >3  as  per  our  current
perative  deﬁnition  for  peripheral  neuropathy  included  a
ajority  of  individuals  with  mild  and  very  few  with  severe
PN.  However,  the  OCT-derived  parameters  have  better
iagnostic  ability  in  differentiating  moderate  or  advanced
tages  of  disease  form  milder  stages.  It  is  well-known
hat  diagnostic  accuracy  and  the  rates  of  disease  detec-
ion  improve  and  are  better  for  identifying  more  advanced
isease.22 Accordingly,  we  believe  that  the  detection  rates
nd  accuracy  would  be  higher  for  differentiating  advanced
r  severe  DPN.
The  RNFL  thickness  has  been  shown  to  decrease  by
0.2  m  per  year  increase  in  age.23,24 In  our  study,  those
ith  DPN  were  on  an  average,  4  years  older;  the  RNFL  thick-
ess  differed  by  12--14  m  between  groups.  The  differences
etween  groups  are  higher  than  demonstrated  test-retest
ariability  in  RNFL  measurements  in  healthy  populations,
uggesting  that  these  ﬁndings  are  not  due  to  chance  alone.25
Diabetic  retinopathy  is  an  undisputed  major  ocular
omplication  of  diabetes  and  has  been  thought  to  underlie
euro-retinal  compromise.26 However,  full  retinal  thickness
nd  inner  retinal  thickness  have  been  shown  to  be  reduced  in
ndividuals  with  diabetes  compared  to  non-diabetic  subjects
n  minimal,27,28 or  no,29,30 clinically  detectable  retinopathy,
uggesting  the  possibility  that  additional  factors  may  be  con-
ributing  to  neuroretinal  compromise.  In  the  present  study,
 higher  proportion  of  individuals  with  DPN  had  DR  com-
ared  to  patients  without  DPN,  as  would  be  expected  as
oth  are  related  to  duration  of  disease.  We  have  previously
hown  that  the  inferior  quadrant  RNFL  thickness10 is  signiﬁ-
antly  reduced  in  individuals  with  DPN,  especially  those  with
evere  DPN  and  high  risk  of  foot  ulceration,  independent  of
R.  Nevertheless,  the  presence  of  macular  edema  or  cot-
on  wool  spots  may  artiﬁcially  elevate  retinal  thickness.  It
s  impractical  to  exclude  those  with  DR  from  the  cohort,
o  as  to  negate  the  inﬂuence  of  subtle  macular  edema,
ecause  DR  and  DPN  are  common  co-morbidities  in  the  pop-
lation.  Deliberate  exclusion  of  those  with  DR  may  result
n  a cohort  that  is  not  truly  representative  of  the  target
opulation.
As  a  method  of  assigning  one  of  the  two  eyes,  we  exam-
ned  the  eye  on  the  side  of  the  dominant  hand  as  reported
y  the  participant.  The  protocol  was  the  same  for  all
articipants  examined.  Therefore,  we  believe  any  errors
ssociated  with  this  assignment  protocol  would  have  been
istributed  similarly  in  cases  and  in  controls.
onclusions
his  study  has  demonstrated  abnormalities  in  a  number  of
etinal  parameters  quantiﬁed  using  OCT  in  patients  with  DPN
ith  limited  sensitivity  but  good  speciﬁcity.  However,  the
tility  of  using  OCT  for  detecting  differences  in  the  same
etinal  parameters  in  individuals  with  minimal  sub-clinicaleﬁned  quantiﬁcation  of  both  the  presence  and  severity  of
europathy  as  well  as  further  reﬁnement  of  the  technol-
gy  and  analytical  approaches  to  quantifying  retinal  layer
Diagnostic  capability  of  SDOCT  in  diabetic  neuropathy  
deﬁcits.  Nevertheless,  OCT  is  a  quick,  easy  and  non-invasive
technique  which  has  been  increasingly  deployed  in  oph-
thalmic  practices,  making  it  a  readily  available  diagnostic
technique  for  neuropathy.
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